Inflarx (NASDAQ:IFRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “
A number of other equities analysts have also weighed in on the company. Credit Suisse Group initiated coverage on Inflarx in a research note on Monday, December 10th. They set an “outperform” rating and a $47.00 price objective on the stock. ValuEngine raised Inflarx from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Robert W. Baird initiated coverage on Inflarx in a research note on Monday. They set an “outperform” rating and a $62.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $46.88.
NASDAQ IFRX opened at $33.32 on Wednesday. The firm has a market cap of $813.73 million, a price-to-earnings ratio of -11.33 and a beta of -0.69. Inflarx has a fifty-two week low of $20.31 and a fifty-two week high of $42.83.
Inflarx (NASDAQ:IFRX) last released its quarterly earnings data on Wednesday, November 21st. The company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.10. Equities analysts forecast that Inflarx will post -1.3 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc raised its position in Inflarx by 137.4% in the third quarter. Vanguard Group Inc now owns 162,460 shares of the company’s stock valued at $5,576,000 after purchasing an additional 94,020 shares during the period. Vanguard Group Inc. raised its position in Inflarx by 137.4% in the third quarter. Vanguard Group Inc. now owns 162,460 shares of the company’s stock valued at $5,576,000 after purchasing an additional 94,020 shares during the period. Scopia Capital Management LP purchased a new stake in Inflarx in the third quarter valued at $7,038,000. Jane Street Group LLC purchased a new stake in Inflarx in the third quarter valued at $278,000. Finally, Renaissance Technologies LLC purchased a new stake in Inflarx in the third quarter valued at $665,000. Institutional investors own 57.10% of the company’s stock.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
See Also: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.